醫學英語新聞第1期:Schizophrenia 精神分裂症

2021-02-13 醫護英語學習

Schizophrenia Could Be Physically Changing The Body, Not Just The Brain

But how?

TOBY PILLINGER, THE CONVERSATION

Schizophrenia [n.精神分裂症] is considered a disorder of the mind, influencing the way a person thinks, feels and behaves. But our latest research shows that organs, other than the brain, also change at the onset of the disease.

Scientists have known for a long time that people with schizophrenia have much higher rates of physical illness compared with the general population, and this contributes to startlingly [adv. 使人驚奇地] high rates of premature [adj. 過早的] death.

People with the disorder die 15 to 20 years earlier than the average person.

This poor physical health has often been seen as a secondary effect of illness. Antipsychotic [adj.治療精神病的] drugs, for example, are associated with an increased risk of weight gain and type 2 diabetes.

Lifestyle factors have been thought to play a part, too. A person with debilitating [adj. 使衰弱的] mental symptoms is more likely to forgo [v.放棄] exercise and have a poor diet.

However, in recent years, scientists have observed that people who have recently been diagnosed with schizophrenia and who aren't on any medication yet show evidence of physiological changes, such as an overactive immune system.

Could it be that schizophrenia is in fact a body-wide disorder?

My colleagues and I examined evidence of physiological changes around the body at the onset of schizophrenia and compared it with evidence of changes within the brain in the same group of people.

We pooled data from multiple studies, examining markers of inflammation [n.炎症], hormone [n.荷爾蒙] levels and heart disease risk factors, including glucose [n.葡萄糖] and cholesterol [n.甘油三酯] levels.

We also pooled data from studies examining brain structure, levels of different chemicals within the brain, and markers of brain activity.

We showed that compared with the general population, early schizophrenia is associated with changes in brain structure and function. We also showed that early schizophrenia is associated with various changes around the body.

We calculated the magnitude [n.大小,量級] of these changes using a statistical measure known as the effect size.

At the onset of schizophrenia, we observed that there was no difference in the effect size for changes within the brain compared with the effect size for changes around the body, suggesting that schizophrenia might indeed be a whole-body disorder, and one that should be treated as such.

Three possible explanations

There are three theories which might explain how alterations within the brain might be associated with alterations around the body in schizophrenia.

First, dysfunction [n.機能障礙] around the body may cause changes in the brain, ultimately leading to schizophrenia. This process has been seen in certain rare cancers that produce antibodies that target the brain and trigger psychosis [n.精神病].

If the tumour is removed, the psychotic experiences improve.

Second, symptoms of schizophrenia may result in physical health disorders. An example of this is the stress of psychosis resulting in raised levels of the steroid [n.甾類化合物,類固醇] hormone cortisol [n.皮質醇,氫化可的松]. High levels of cortisol are associated with weight gain, diabetes and raised blood pressure.

Third, symptoms of schizophrenia and physical health disorders may arise via different mechanisms but from a common risk factor.

An example of this is how famine experienced by a pregnant mother increases the chances of her child developing both diabetes and schizophrenia in adult life.

The increased risk of schizophrenia may be due to impaired development of the child's brain as a result of the mother's malnutrition [n.營養不良]. The increased risk of diabetes may be due to changes in the child's ability to metabolise [v.新陳代謝] glucose, again a result of the mother's malnutrition.

Work still to be done

We need to do more work to figure out whether changes around the body are a cause or a consequence of schizophrenia.

One approach is to look at those people who are at risk of developing schizophrenia to see how changes around the body evolve in the ones who develop schizophrenia compared with those who don't.

More work is also needed to see how changes around the body respond to changes in the severity of symptoms of schizophrenia.

Finally, most premature deaths seen in schizophrenia are due to cardiovascular disease. Life expectancy in schizophrenia has failed to improve over recent decades. Studies are needed to determine if addressing physical health early on will reduce mortality [n.死亡率]  in schizophrenia.

Toby Pillinger, Doctor and Clinical Researcher, King's College London.

……

相關焦點

  • Schizophrenia 精神分裂症
    The term schizophrenia comes from Greek words meaning 「split mind.」 However, contrary to common belief, schizophrenia does not refer to a person with a split personality or multiple personality.
  • 靈北終止一精神分裂症新藥的二期臨床研究
    這一決定是基於一項中期分析得出的結果,其結論指出:這項試驗不太可能在其主要終點,即實現從基線檢查到第12周患者的簡明陰性症狀量表(BNSS)的平均變化達到統計顯著性。但停止試驗不涉及安全考慮。據悉,這項2期臨床研究的主要目的是評價兩劑Lu AF11167與安慰劑單藥治療精神分裂症和持續顯著陰性症狀的療效。次要目標是評價Lu AF11167對患者功能的療效以及該化合物的安全性和耐受性。
  • CCRT對精神分裂症認知功能的研究進展
    [1]魏欽令,鄭倆榮,胡冰,等.首發未服藥精神分裂症患者腦彌散張量成像的基於體素分析[J].中華神經醫學雜誌,2011,10(9):926-928.[2]Mesholam-Gately RI,Giuliano AJ,Goff KP,et a1.
  • 精神分裂症基因存在罕見變體
    精神分裂症基因存在罕見變體 作者:小柯機器人 發布時間:2020/1/15 13:43:29 英國卡迪夫大學Michael J. Owen和Michael C.
  • 每日一詞·schizophrenia
    點擊上述藍字關注公眾號B站同名:醫學英語詞彙
  • 精神分裂症是什麼?
    Transcript What is schizophrenia (/ˌskidzəu'freniə/精神分裂症)?Although auditory hallucinations (幻聽) are most common, a person with schizophrenia may also see, smell or hear something that is not there.
  • Nat.Medicine:科學家發現治療精神分裂症的新藥
    生物谷報導:一項臨床試驗發現,一種以穀氨酸調控的神經傳遞素為靶標的新藥能有效地治療精神分裂症,新成果發表在9月號的《自然—醫學》期刊上。對精神分裂症而言,所有常用的處方安定藥均以多巴胺受體為靶標。如今,Sandeep Patil和同事報告:一種特別的穀氨酸受體亞型mGlu2/3是一種選擇性激動素,它對精神分裂症患者有安定作用。
  • 醫學英語:心理學詞彙8
    personality disorder   分裂樣人格障礙 schizoid personality disorder   表演型人格障礙 histrionic personality disorder   自戀型人格障礙 narcissistic personality disorder   精神病 psychosis   精神質
  • 精神分裂症突破性藥物!首個非多巴胺D2受體結合的藥物SEP-363856...
    NEJM上發表的是一項4周、隨機、雙盲、平行組、安慰劑對照、靈活劑量、多中心研究,在精神分裂症急性發作的成人患者中開展,評估了SEP-363856的療效和安全性。研究中,患者以1:1的比例隨機分組,分別接受為期4周的每日1次SEP-363856(50mg或75mg)或安慰劑治療。
  • Transl Psych:蛋白質水平改變或幫助開發精神分裂症的新療法
    ,本文研究為理解精神分裂症如何影響大腦的功能,同時幫助開發新型藥物療法提供了一定幫助。如今研究者發現很多遺傳突變都和大腦功能有關,因為其可以控制細胞功能,比如蛋白的合成等,如果蛋白質的合成被輕微影響,那麼許多細胞的功能就會受到微妙地改變,這就會影響精神分裂症患者的大腦發育以及成年個體的大腦功能。
  • fMRI可識別精神分裂症的嚴重程度
    選擇這個測試是因為聽覺問題是精神分裂症的常見症狀。研究人員使用稱為「連結權重」的計算方法,將精神分裂症患者腦活動的相對強度與對照組相比較。其中涉及大腦或節點的不同群集之間的神經信號。平均而言,精神分裂症患者在幾個腦區域比對照組更活躍,特別是在連接丘腦和運動皮層的區域中。
  • JAMA:穀氨酸鹽與精神分裂症
    這一研究結果提示,穀氨酸鹽在精神分裂症中可能扮演重要角色。磁共振波譜學分析顯示,在基線時,24名精神病初發的受試者右側「聯合紋狀體」(associative striatum)中穀氨酸鹽的平均水平為31.34IU,而這一數字在18名精神健康對照中為28.23IU。這一對比趨勢與研究者所設想的相符。
  • 幹細胞對精神分裂症的新探索
    精神分裂症(schizophrenia,SCZ)是一種高致殘率的精神疾病,其發病機制有多種假說,如神經幹細胞的發育障礙、免疫功能減退、增殖水平降低引起神經網絡失衡等。2020年4月,我國學者黃等人報導了臍帶間充質幹細胞對精神分裂症的應用前景,他認為目前精神分裂症的臨床面臨的困境是其陰性症狀和認知功能障礙難以緩解,利用幹細胞改善上述症狀的治療策略是全新的思路。
  • 精神分裂症或是一種免疫系統疾病
    最近,有研究人員發現精神分裂症與人體免疫性疾病有關聯,這一發現對於精神疾病成因研究有著重要意義,有助於科學家們找到更為有效的精神分裂症療法。炎性和自身免疫性疾病在精神分裂症患者中更為常見,這表明這些疾病有共同病因。目前,尚無在精神分裂症中使用免疫抑制劑甲氨蝶呤的試驗。於是,研究人員進行了低劑量甲氨蝶呤治療精神分裂症效果的實驗。研究人員首先從巴基斯坦喀拉蚩的住院和門診機構招募了患病5年內,年齡在18至35歲之間的精神分裂症患者92名。他們被隨機分配為2組。
  • 我國科學家在精神分裂症調控紊亂機制研究中取得系列進展
    精神分裂症是常見的、危害極大的重性精神疾病,其發病機理迄今未明,既往研究提示精神分裂症是基因變異和/或調控障礙的結果。轉錄因子、微小RNA(miRNA)和長非編碼RNA(lncRNA)是重要的基因調控因子。
  • 精神分裂症新藥!Intra-Cellular Therapies公司Caplyta(lumate...
    精神分裂症(schizophrenia)是一種嚴重的精神疾病,影響美國約240萬成年人。精神分裂症的臨床表現多種多樣。急性發作的特點是精神病症狀,包括幻覺和妄想,往往需要住院治療。這種疾病是慢性和終身的,常伴有抑鬱和社會功能和認知能力的逐漸惡化。精神分裂症患者常因體重增加和運動障礙等副作用而停止治療。
  • 精神分裂症的高危因素及外周生物標記物:傘狀綜述
    精神分裂症的終生患病率約為千分之四,通常起病於青少年期及成年早期,不僅具有很高的致殘性,患者過早死亡的風險也遠高於一般人群:年輕時,精神分裂症患者的自殺率更高;隨著年齡的增加,心血管代謝疾病逐漸成為這一群體的頭號殺手。
  • 時隔16年,美國精神醫學學會(APA)發布新版精神分裂症治療指南
    APA新版精神分裂症指南(一):選擇抗精神病藥APA新版精神分裂症指南(二):抗精神病藥起始治療2019年12月,美國精神醫學學會(APA)董事會批准通過了第3版《APA精神分裂症患者治療實踐指南》,指南全文近日正式發表於
  • 精神分裂症和抑鬱症功能基因組學研究取得進展
    精神分裂症和抑鬱症等精神疾病是影響人類健康的公共衛生難題,由於該類疾病發病機制尚未完全清楚,對其診療常存在困難。近年來,世界範圍內的全基因組關聯分析(GWAS)報導許多非編碼變異與精神疾病相關,這些變異是否存在生物學功能及相關機制仍需探索。
  • 精神分裂症及焦慮障礙診療新進展|引「精」聚「點」 ·第24 期
    為使國內精神科醫生能夠了解到這些新進展,住友製藥醫學聯絡部特設「新·思界」論壇,圍繞這些新的研究展開精彩分享和討論。 本次「新 · 思界」國際熱點會,邀請到魯豫兩省精神科、心理科、神經內科知名專家齊聚鄭州,共同探討2020年精神分裂症、焦慮障礙診療的新進展。